CollPlant Biotechnologies Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

CollPlant Biotechnologies wird ein Gewinn- und Umsatzwachstum von 61.1% bzw. 30.3% pro Jahr prognostiziert, während der Gewinn pro Aktie um 59.7% pro Jahr wachsen soll.

Wichtige Informationen

61.1%

Wachstumsrate der Gewinne

59.7%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.5%
Wachstumsrate der Einnahmen	30.3%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	30 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 22

Recent updates

We're Interested To See How CollPlant Biotechnologies (NASDAQ:CLGN) Uses Its Cash Hoard To Grow

Feb 03

Is CollPlant Biotechnologies (NASDAQ:CLGN) In A Good Position To Deliver On Growth Plans?

Nov 02

CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) Shares Lagging The Industry But So Is The Business

Sep 06

Here's Why We're Watching CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation

Jul 14

Here's Why We're Not Too Worried About CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation

Mar 02

Companies Like CollPlant Biotechnologies (NASDAQ:CLGN) Are In A Position To Invest In Growth

Nov 10

CollPlant Non-GAAP EPS of -$0.36, revenue of $0.07M

Aug 25

We Think CollPlant Biotechnologies (NASDAQ:CLGN) Can Afford To Drive Business Growth

Jul 22

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 22

CollPlant Biotechnologies - A Cheap, Game-Changing Bio-Printing Platform Company

Aug 05

Why We Think Shareholders May Be Considering Bumping Up CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) CEO Compensation

Jul 29

The Strong Earnings Posted By CollPlant Biotechnologies (NASDAQ:CLGN) Are A Good Indication Of The Strength Of The Business

Jun 09

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:CLGN - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	22	0	N/A	N/A	1
12/31/2025	15	-6	N/A	N/A	1
12/31/2024	3	-17	N/A	N/A	1
3/31/2024	11	-7	-3	-3	N/A
12/31/2023	11	-7	-4	-3	N/A
9/30/2023	11	-7	-5	-4	N/A
6/30/2023	11	-7	-15	-14	N/A
3/31/2023	1	-17	-15	-14	N/A
12/31/2022	0	-17	-15	-14	N/A
9/30/2022	1	-16	-14	-13	N/A
6/30/2022	1	-15	-14	-12	N/A
3/31/2022	1	-14	-14	-12	N/A
12/31/2021	16	0	1	3	N/A
9/30/2021	16	1	2	3	N/A
6/30/2021	20	5	7	8	N/A
3/31/2021	20	6	9	9	N/A
12/31/2020	6	-6	-5	-4	N/A
9/30/2020	6	-7	-5	-4	N/A
6/30/2020	3	-11	-8	-7	N/A
3/31/2020	2	-11	-8	-7	N/A
12/31/2019	2	-11	-7	-6	N/A
9/30/2019	6	-6	-2	-1	N/A
6/30/2019	6	-6	-2	-1	N/A
3/31/2019	5	-4	-2	-1	N/A
12/31/2018	5	-6	-2	-1	N/A
9/30/2018	1	-6	-7	-6	N/A
6/30/2018	1	-6	-6	-6	N/A
3/31/2018	1	-7	-5	-5	N/A
12/31/2017	0	-6	N/A	-5	N/A
9/30/2017	0	-6	N/A	-5	N/A
6/30/2017	0	-7	N/A	-5	N/A
3/31/2017	0	-7	N/A	-5	N/A
12/31/2016	0	-7	N/A	-5	N/A
9/30/2016	0	-7	N/A	-5	N/A
6/30/2016	N/A	-7	N/A	-5	N/A
3/31/2016	N/A	-6	N/A	-5	N/A
12/31/2015	N/A	-5	N/A	-4	N/A
9/30/2015	N/A	-4	N/A	-4	N/A
6/30/2015	N/A	-4	N/A	-4	N/A
3/31/2015	N/A	-3	N/A	-3	N/A
12/31/2014	N/A	-3	N/A	-3	N/A
9/30/2014	N/A	-4	N/A	-4	N/A
6/30/2014	N/A	-4	N/A	-4	N/A
3/31/2014	N/A	-4	N/A	-4	N/A
12/31/2013	N/A	-5	N/A	-4	N/A
9/30/2013	N/A	-5	N/A	-3	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CLGN wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.4%).

Ertrag vs. Markt: CLGN wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: CLGN wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: CLGNDie Einnahmen des Unternehmens (30.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: CLGNDie Einnahmen des Unternehmens (30.3% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von CLGN in 3 Jahren voraussichtlich hoch sein wird

CollPlant Biotechnologies Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus estimates of losses per share improve by 43%

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Recent updates

Collplant Successfully Bio-Prints 200Cc Commercial-Size Regenerative Breast Implants and Reports Additional Positive Pre-Clinical Data

CollPlant Biotechnologies Ltd. to Report Q1, 2024 Results on May 29, 2024

New minor risk - Profitability

Full year 2023 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

CollPlant Biotechnologies Ltd. to Report Fiscal Year 2023 Results on Apr 04, 2024

We're Interested To See How CollPlant Biotechnologies (NASDAQ:CLGN) Uses Its Cash Hoard To Grow

CollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants

New minor risk - Profitability

CollPlant Biotechnologies Ltd. to Report Q3, 2023 Results on Nov 29, 2023

Is CollPlant Biotechnologies (NASDAQ:CLGN) In A Good Position To Deliver On Growth Plans?

New minor risk - Share price stability

CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) Shares Lagging The Industry But So Is The Business

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

CollPlant Biotechnologies Ltd. to Report Q2, 2023 Results on Aug 24, 2023

Here's Why We're Watching CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation

Consensus estimates of losses per share improve by 43%

New minor risk - Shareholder dilution

CollPlant Biotechnologies Ltd., Annual General Meeting, Jul 18, 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: EPS exceeds analyst expectations

Here's Why We're Not Too Worried About CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation

CollPlant Announces Successful Pre-Clinical Results in 3D Bioprinted Regenerative Breast Implants Porcine Study and Full Achievement of Objectives

Collplant Enriches Portfolio of Rhcollagen-Based Bioinks with Launch of Collink.3Dtm 50L in Powder Form

Third quarter 2022 earnings released: US$0.40 loss per share (vs US$0.29 loss in 3Q 2021)

Companies Like CollPlant Biotechnologies (NASDAQ:CLGN) Are In A Position To Invest In Growth

Collplant Expands Rhcollagen-Based Bioink Platform with Launch of Collink.3D 90

First half 2022 earnings released: US$0.74 loss per share (vs US$0.91 profit in 1H 2021)

CollPlant Non-GAAP EPS of -$0.36, revenue of $0.07M

We Think CollPlant Biotechnologies (NASDAQ:CLGN) Can Afford To Drive Business Growth

CollPlant Advances its 3D Bioprinted Regenerative Breast Implants into Porcine Study

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2021 earnings released: US$0.29 loss per share (vs US$0.10 profit in 3Q 2020)

Deputy CEO & CFO notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Investor sentiment improved over the past week

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Second quarter 2021 earnings released: US$0.30 loss per share (vs US$0.28 loss in 2Q 2020)

CollPlant Biotechnologies - A Cheap, Game-Changing Bio-Printing Platform Company

Why We Think Shareholders May Be Considering Bumping Up CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) CEO Compensation

The Strong Earnings Posted By CollPlant Biotechnologies (NASDAQ:CLGN) Are A Good Indication Of The Strength Of The Business

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken